Ocugen Inc (OCGN)
$0.31
0.01 (1.72%)
OCGN Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.33M
Day's Range
0.30 - 0.31
52-Week Range
0.17 - 0.96
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
Biotech Speculators Should Try a Small Position in Ocugen Stock
Probably because it's not a buzzworthy coronavirus stock, you might not hear much about OCGN stock but it still has strong upside potential.
Don’t Be Deceived: There’s No Reason to Speculate on Ocugen
Ocugen continues to conduct at-the-market offerings to raise capital. But with a distant payoff, OCGN stock offers too much risk and not enough reward.
If the FDA Can’t Help Ocugen Stock, You Have to Wonder Who Can
Because of the pandemic, OCGN stock attracts speculative interest. But it is not likely to pay off in the long-run
Why the Coronavirus May Have Disrupted Ocugen
In analyzing the science behind OCGN stock, the innovation is quite profound. However, it’s this very platform that is under serious scrutiny thanks to the coronavirus.
The Risk-Reward Ratio of Ocugen Stock Is Positive
OCGN stock isn't the next great biotech play, but savvy traders can limit its risk.
The Math Simply Doesn’t Favor Ocugen Stock
Because of the dynamics of the new normal, troubled names like OCGN stock continue to attract speculative interest. Perhaps some math will finally dissuade these gamblers?
For Biopharma Ocugen, Think Speculation In Small Doses
While Ocugen is unprofitable and in bad need of cash, OCGN stock could soar if its eye disease therapies see clinical success.
Make Sure You Understand the Risks Before Speculating on Ocugen Stock
Ocugen is raising cash through its orphan drug designation, but it still faces risks. Make sure you treat OCGN stock as a speculation.
Ocugen Needs Too Much Time and Too Much Cash
OCGN stock has held up despite the failure of what was its flagship drug. The remaining pipeline simply isn't strong enough for investors to risk more capital.
It’s Best to Avoid Ocugen Stock at the Moment
Until we begin to see solid trial results, OCGN stock could easily plunge back to 20 cents a share. Avoid investing in Ocugen for now.
Ocugen Stock Looks Like a Really Good Short Candidate Here
There's a good deal of downside risk, but Ocugen is worth a look. OCGN stock is likely to fall as Ocugen raises $30 million or 54% of its equity to fund operations over the next 2 plus years.
Don’t Waste Your Time With Long-Shot Penny Stock Ocugen
Recent news helps the odds for OCGN stock, but speculators have gotten carried away. Don't waste your time (or risk your capital) with this.
There’s No Money to Be Made From Buying Ocugen Stock
Ocugen has no revenue and is years away from developing a product. While the cause of developing therapies to fight blindness is laudable, there's no money to be made with OCGN stock.
There’s a Reason Why Ocugen Is a Last Resort in Eye Care
Ocugen got good news Aug. 14 announcing a fourth orphan drug designation for its ophthalmology gene therapy. OCGN stock is still a longshot.
Be Sure You’re Clearly Seeing What’s Happening at Ocugen
OCGN stock has been a hot penny stock. But no revenue and a lead candidate that is years away, are reminders that Ocugen is still a penny stock.
Execution Challenges Could Short-Circuit the Big Ocugen Stock Rally
Some red-hot penny stocks are worth chasing; OCGN stock is not one of them. In fact, this rally is worth fading.
A New Orphan Drug Designation Gives Hope to Ocugen Stock
The FDA just gave a special designation to one of Ocugen's flagship products. That is good for science and it's great for OCGN stock.
Ocugen Investors Are Missing the Obvious Signs of Failure
Initially, the stupendous rise of OCGN stock may give you the case of the FOMOs. But don’t let that emotions guide you as Ocugen is driven by completely irrational actors.
What’s Next For Ocugen After Scoring Orphan Drug Status
Ocugen got a crucial piece of good news from the FDA. But with the company's lead drug years from approval, OCGN stock remains speculative.
There Are So Many Stocks to Buy — Ocugen Isn’t One of Them
Ocugen just doesn't have the qualities that make it attractive to me. Particularly under a buck, OCGN stock is one to avoid.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
C
